Abstract:Sphingomyelin plays a very important role both in cell membrane formation that may well have an impact on the development of diseases like atherosclerosis and diabetes. However, the molecular mechanism that governs intracellular and plasma membrane SM levels is largely unknown. Recently, two isoforms of sphingomyelin synthase (SMS1 and SMS2), the last enzyme for SM de novo synthesis, have been cloned. We have hypothesized that SMS1 and SMS2 are the two most likely candidates responsible for the SM levels in the cells and on the plasma membrane. To test this hypothesis, cultured cells were treated with tricyclodecan-9-yl-xanthogenate (D609), an inhibitor of SMS, or with SMS1 and SMS2 siRNAs. Cells were then pulsed with [14C]-L-serine (a precursor of all sphingolipids). SMS activity and [14C]-SM in the cells were monitored. We found that SMS activity was significantly decreased in cells after D609 or SMS siRNA treatment, compared with controls. SMS inhibition by D609 or SMS siRNAs significantly decreased intracellular [14C]-SM levels. We measured cellular lipid levels, including SM, ceramide, phosphatidylcholine, and diacylglycerol and found that SMS1 and SMS2 siRNA treatment caused a significant decrease of SM levels (20% and 11%, respectively), compared to control siRNA treatment; SMS1 but not SMS2 siRNA treatment caused a significant increase of ceramide levels (10%). There was a decreasing tendency for diacylglycerol levels after both SMS1 and SMS2 siRNA treatment, however, it was not statistical significant. As shown by lipid rafts isolation and lipid determination, SMS1 and SMS2 siRNA treatment led to a decrease of SM content in detergent-resistant lipid rafts on the cell membrane. Furthermore, SMS1 and SMS2 siRNA-treated cells had a stronger resistance than did control siRNA-treated cells to lysenin (a protein that causes cell lysis due to its affinity for plasma membrane SM). These results indicate that both SMS1 and SMS2 contribute to SM de novo synthesis and control SM levels in the cells and on the cell membrane including plasma membrane, implying an important relationship between SMS activity and cell functions.

The Sphingomyelin Synthase Family: Proteins, Diseases, and Inhibitors

Sphingomyelin Synthase Family and Phospholipase Cs

Inhibition of Sphingomyelin Synthase (SMS) Affects Intracellular Sphingomyelin Accumulation and Plasma Membrane Lipid Organization.

The domain responsible for sphingomyelin synthase (SMS) activity.

Identification of Small Molecule Sphingomyelin Synthase Inhibitors.

Abstract 410: Effect of Total Sphingomyelin Synthase Activity on Low Density Lipoprotein Catabolism

Molecular Modeling of the Three-Dimensional Structure of Human Sphingomyelin Synthase

Sphingomyelin Biosynthesis: Its Impact on Lipid Metabolism and Atherosclerosis

Sphingomyelin Synthase 2 is One of the Determinants for Plasma and Liver Sphingomyelin Levels in Mice

Impact of Sphingomyelin Synthase 1 Deficiency on Sphingolipid Metabolism and Atherosclerosis in Mice

Cryo-EM Structure of Human Sphingomyelin Synthase and Its Mechanistic Implications for Sphingomyelin Synthesis

Sphingolipids and their metabolism in physiology and disease

Molecular Basis for the Catalytic Mechanism of Human Neutral Sphingomyelinases 1 (Hsmpd2).

Development of a Quantitative Biochemical and Cellular Sphingomyelin Synthase Assay Using Mass Spectrometry

Sphingomyelin Synthase 2 Activity and Liver Steatosis

Effect of Total SMS Activity on LDL Catabolism in Mice.

Subcellular Targeting Domains of Sphingomyelin Synthase 1 and 2

Discovery of the Selective Sphingomyelin Synthase 2 Inhibitors with the Novel Structure of Oxazolopyridine

The Role of Sphingomyelin Synthase 2 (SMS2) in Platelet Activation and Its Clinical Significance

SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis

Selective Reduction in the Sphingomyelin Content of Atherogenic Lipoproteins Inhibits Their Retention in Murine Aortas and the Subsequent Development of Atherosclerosis.